Caris Life Sciences study links ESR1 L536 mutations to shorter elacestrant treatment duration
CAI•A Caris Life Sciences study found certain ESR1 variants, multiple mutations and lower estrogen receptor pathway activity were associated with shorter elacestrant treatment duration in metastatic breast cancer.
1. Study findings
Caris Life Sciences published a study in Clinical Cancer Research examining molecular differences in ESR1-mutated metastatic breast cancer. The findings suggest comprehensive molecular profiling could provide information beyond mutation status alone, but require prospective validation before guiding clinical decisions.
